Skip to content
National Brain Tumor Society | Brain Tumor Investment Fund

Oligodendroglioma Research Fund

Through the Community Research Fund Program, the Oligodendroglioma Research Fund supports promising research specifically targeted at creating new treatments for oligodendroglioma and improving patients’ lives.

From 2013 to today, NBTS has funded a total of $2 million in grants to 11 researchers across nine different institutions, all focused on oligodendroglioma and related low-grade glioma research. During this period, NBTS’s strategy to address the problem has focused on funding research projects that revealed genetic risk factors, established models capable of testing potential treatments, built scientific infrastructure to predict if treatments will work, launched novel therapeutic approaches, and helped propel a groundbreaking treatment toward a pivotal clinical trial lead by a biopharma prepared to bring a new therapy to patients.

The latest Oligodendroglioma Research Progress Report focuses specifically on NBTS funded research related to oligodendroglioma. It describes results over a seven-year time span and exciting next steps to drive research forward aimed at novel treatments and ultimately, cures.

Support the Oligo Research Fund

To direct your gift to the Oligodendroglioma Research Fund, go to our donation page and select “direct my gift” under the Gift Designation header. The menu will provide an option to support the Oligodendroglioma Research Fund.

Give Now Download Progress Report

Funded Projects Include:

  • Innovative Models Developed for Testing Treatments
    Dr. Anders Persson, University of California San Francisco
  • New Strategy Identified for Eliminating Brain Tumors
    Drs. Mario Suva & David Louis, Massachusetts General Hospital
  • Targeting Mutant IDH 1/2 with Vorasidenib (AG-881) in Low-Grade Gliomas
    Dr. Ingo Mellinghoff, Memorial Sloan Kettering Cancer
  • Leads Discovered About the Causes of Brain Cancer
    Drs. Robert Jenkins & Daniel Lachance, Mayo Clinic
  • Registry Built to Learn from Every Patient and Determine Response to Treatment
    Dr. Elizabeth Claus, Yale University
  • Identifying Risk Factors for Oligodendroglioma
    Drs. Robert Jenkins & Daniel Lachance, Mayo Clinic
  • AI Platform Established to Predict Brain Tumor Behavior
    Dan Brat and Lee Cooper, Emory and Northwestern University
  • International Consortium of Researchers Establishes Open Dataset Tracking Low-Grade Gliomas including Oligodendroglioma
    Dr. Roel Verhaak, The Jackson Laboratory
  • Triggering the Body’s Immune System to Fight Back
    Dr. Samuel Cheshier, Standford

Stay Informed & Connected